Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment
Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment
About this item
Full title
Author / Creator
Publisher
England: Taylor & Francis
Journal title
Language
English
Formats
Publication information
Publisher
England: Taylor & Francis
Subjects
More information
Scope and Contents
Contents
Objective: The development of nanosuspension for targeted delivery of glibenclamide as hypoglycemic agent to the lung in an inhaler dosage form.
Method: Glibenclamide nanosuspension formulations were prepared using Box-Behnken design to investigate the effect of independent factors on the dependent variables, Fourier-transform Infrared spectrosc...
Alternative Titles
Full title
Glibenclamide nanosuspension inhaler: development, in vitro and in vivo assessment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_32250179
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_32250179
Other Identifiers
ISSN
0363-9045
E-ISSN
1520-5762
DOI
10.1080/03639045.2020.1753062
